Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person In normal development vascular endothelial growth factors (V...
| Class:Id | Summation:9685053 |
|---|---|
| _displayName | In normal development vascular endothelial growth factors (V... |
| _timestamp | 2020-04-24 15:31:02 |
| created | [InstanceEdit:9685099] Jassal, Bijay, 2020-04-22 |
| literatureReference | [LiteratureReference:9685086] Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis [LiteratureReference:9685085] Contribution of Angiogenesis to Inflammation and Cancer [LiteratureReference:9685113] Treatment of Diabetic Macular Edema [LiteratureReference:9685116] Clinical trials on drug repositioning for COVID-19 treatment |
| modified | [InstanceEdit:9685670] Jassal, Bijay, 2020-04-24 |
| text | In normal development vascular endothelial growth factors (VEGFs) are crucial regulators of vascular development during embryogenesis (vasculogenesis) and blood-vessel formation in the adult (angiogenesis). In tumor progression, activation of VEGF pathways promotes tumor vascularization, facilitating tumor growth and metastasis. Abnormal VEGF function is also associated with inflammatory diseases including atherosclerosis, and hyperthyroidism. Inhibition of this process may provide clinical benefits to patients suffering from cancer, diabetic macular edema (DME) and age-related macular degeneration (AMD). VEGFA inhibitors are therapeutic options for these diseases (Melincovici et al. 2018, Aguilar-Cazares et al. 2019, Kim et al. 2019). Aflibercept is a recombinant protein which is indicated for DME, AMD and part of a combined treatment for metastatic colorectal cancer (Chu 2009, Tang & Moore 2013). Abicipar Pegol (MP0112) is an investigational compound that has been used in trials studying the treatment of DME and AMD (Campochiaro et al. 2013). Brolucizumab (RTH258, ESBA1008,4) is a monoclonal antibody indicated to treat AMD (Yannuzzi et al. 2019). Pegaptanib is a polynucleotide aptamer used to treat AMD (Gragoudas et al. 2004, Vinores 2006). Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. It is indicated for the treatment of DME and AMD (Nguyen et al. 2006, Ferrara et al. 2006). Vanucizumab is an investigational monoclonal antibody that has been used in trials studying the treatment of colorectal cancer and advanced/metastatic solid tumours (Hidalgo et al. 2018, Bendell et al. 2019). Bevacizumab (Avastin) is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and inhibiting VEGFA (Papachristos et al. 2019). Researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies. Bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19 (Phase 2/3 NCT04275414) (Rosa & Santos 2020). |
| (summation) | [Reaction:9679477] VEGFA-165 dimer binds VEGFA inhibitors [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by In normal development vascular endothelial growth factors (V... (9685053)
